ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 1, 2017, OncoMed Pharmaceuticals, Inc. (the Company) held
its 2017 Annual Meeting of Stockholders (the 2017 Annual
Meeting). At the 2017 Annual Meeting, the stockholders of the
Company voted on the following proposals, each of which is
described in the Companys Definitive Proxy Statement on Schedule
14A filed with the Securities and Exchange Commission on April
13, 2017, as supplemented (the Proxy Statement):
Proposal 1:Election of Directors.
The stockholders elected the following individuals to the
Companys Board of Directors:
|
Nominee |
For |
Withheld |
Broker Non-Vote |
Uncast |
|
Perry A. Karsen |
25,184,343 |
453,016 |
7,461,208 |
|
|
Rick E Winningham |
23,979,711 |
1,657,648 |
7,461,208 |
|
|
Michael S. Wyzga |
25,497,390 |
139,969 |
7,461,208 |
|
Proposal 2: Ratification of Appointment of Independent Registered
Public Accounting Firm.
The stockholders ratified and approved the appointment of Ernst
Young LLP as the Companys independent registered public
accounting firm for the fiscal year ending December 31, 2017.
|
For |
Against |
Abstain |
Broker Non-Vote |
Uncast |
|
32,887,128 |
164,553 |
46,886 |
About ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED)
OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company’s Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company’s Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.
